biostudies-literatureUnknown12Prelaj A<h4>Introduction</h4>Artificial Intelligence (AI) methods are being increasingly investigated as a means to generate predictive models applicable in the clinical practice. In this study, we developed a model to predict the efficacy of immunotherapy (IO) in patients with advanced non-small cell lung cancer (NSCLC) using eXplainable AI (XAI) Machine Learning (ML) methods.<h4>Methods</h4>We prospectively collected real-world data from patients with an advanced NSCLC condition receiving immune-checkpoint inhibitors (ICIs) either as a single agent or in combination with chemotherapy. With regards to six different outcomes - Disease Control Rate (DCR), Objective Response Rate (ORR), 6 and 24-month Overall Survival (OS6 and OS24), 3-months Progression-Free Survival (PFS3) and Time to Treatment FaFrontiers in oncology1078822https://www.ebi.ac.uk/biostudies/studies/S-EPMC9899835biostudies-literatureReal-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients.PMC9899835Zanitti Mde Braud FGMPedrocchi ALGGarassino MCMazzeo LBottiglieri ASpagnoletti ASignorelli DPesenti MRametta APrelaj AGalli GRinaldi APedica BTrovo FMarinacci RPircher CCDe Toma ABeninato TGanzinelli MProto CDi Mauro MRBrambilla MKosta SViscardi GFerrara RGiani CGalli EGMiskovic VAntonia MDi Gregorio SLo Russo GProvenzano LOcchipinti MRestelli MManglaviti SfalseReal-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients.<h4>Introduction</h4>Artificial Intelligence (AI) methods are being increasingly investigated as a means to generate predictive models applicable in the clinical practice. In this study, we developed a model to predict the efficacy of immunotherapy (IO) in patients with advanced non-small cell lung cancer (NSCLC) using eXplainable AI (XAI) Machine Learning (ML) methods.<h4>Methods</h4>We prospectively collected real-world data from patients with an advanced NSCLC condition receiving immune-checkpoint inhibitors (ICIs) either as a single agent or in combination with chemotherapy. With regards to six different outcomes - Disease Control Rate (DCR), Objective Response Rate (ORR), 6 and 24-month Overall Survival (OS6 and OS24), 3-months Progression-Free Survival (PFS3) and Time to Treatment Fa2022-01-01T00:00:00Z20222025-04-04T12:56:23.205Z2025-04-04T12:56:23.205ZS-EPMC98998353675585610.3389/fonc.2022.1078822